Received Apr 10, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (MODERNA)) | MODERNA | 4 | B0005 | IM / RA |
| FLU3 | INFLUENZA (SEASONAL) (FLUCELVAX) | SEQIRUS, INC. | N/A | 391417 | IM / LA |
No adverse event reported. Reporting this VAERS per Moderna after a temperature excursion, vaccine remained viable after the excursion per Moderna.
None reported
postconcussion syndrome, mixed irritable bowel syndrome, restlessness and agitation, cannabis use disorder, nightmares, umbilical hernia, poor short term memory, vitamin d deficiency, pure hypercholesterolemia, history of colonic polyps
hydroxyzine HCL, ibuprofen, dicyclomine, atorvastatin
No known allergies
N/A